Peptide Cycling Principles — Receptor Desensitization and Protocol Design
GH secretagogue receptor (GHSR) downregulates with continuous ghrelin-mimetic stimulation. Standard cycling: 8–12 weeks on / 4–8 weeks off for GH peptides to restore pituitary sensitivity.
| Measure | Value | Unit | Notes |
|---|---|---|---|
| GH Peptide Max Continuous Use | 12 | weeks | Standard ceiling for continuous GH secretagogue use before somatotroph receptor desensitization reduces efficacy; break recommended after |
| BPC-157 / TB-500 Cycle | 4–6 / 4–6 | weeks on / weeks off | Tissue repair peptides; no proven receptor desensitization mechanism but cycling widely practiced; no human data on optimal schedule |
| Semaglutide Cycling | None required | protocol | Chronic administration without cycling is the FDA-approved protocol; GLP-1R does not significantly desensitize with weekly subcutaneous dosing |
| GHSR Desensitization | Documented | mechanism | Growth hormone secretagogue receptor (GHSR) shows agonist-induced internalization and desensitization with continuous stimulation — basis for GH peptide cycling rationale |
| Break Duration (GH peptides) | 4–8 | weeks minimum | Standard off-cycle period to restore pituitary GH axis sensitivity; no human data on optimal duration |
| Semax/Selank Cycle | 10–14 | days on / 2–4 weeks off | Russian clinical standard for intranasal cognitive peptides; based on institutional clinical practice, not receptor desensitization data |
Why Cycling Matters — Receptor Biology
Peptide cycling protocols exist because many peptides produce their effects through receptors that can desensitize, downregulate, or internalize with continuous stimulation. This is not universal across all peptide classes — some peptides work through mechanisms where continuous use is appropriate, while others become progressively less effective without breaks.
Understanding the mechanistic basis (or lack thereof) for cycling recommendations separates evidence-based practice from community convention.
Cycling Rationale by Peptide Class
| Peptide Class | Cycling Required? | Mechanism | Evidence Level |
|---|---|---|---|
| GH secretagogues (ipamorelin, GHRP-2, GHRP-6, CJC-1295) | Yes | GHSR agonist-induced internalization and desensitization | C (mechanistic); community convention for duration |
| GLP-1/GIP agonists (semaglutide, tirzepatide) | No | Receptor does not significantly desensitize at clinical doses | A (FDA-approved chronic protocol) |
| Tissue repair (BPC-157, TB-500) | Precautionary | No clear desensitization mechanism; unknown long-term effects | D (convention only) |
| Cognitive peptides (Semax, Selank) | Short cycles recommended | Russian clinical protocol; possible tachyphylaxis at longer use | B (Russian practice), C (Western) |
| Longevity peptides (Epitalon) | Long breaks | Khavinson’s protocol: 10–20 day courses with months between | D (Khavinson’s convention) |
| Collagen/matrix peptides (GHK-Cu, collagen peptides) | No strong rationale | Substrate-driven effects; no receptor saturation mechanism | D (convention varies) |
GH Peptide Cycling Table
| Peptide | On-Cycle Duration | Break Duration | Rationale | Protocol Source |
|---|---|---|---|---|
| Ipamorelin (alone) | 8–12 weeks | 4–8 weeks | GHSR desensitization | Community convention; PMID 9849822 mechanistic basis |
| CJC-1295 (no DAC) | 8–12 weeks | 4–8 weeks | GHRH receptor saturation | Community convention |
| CJC-1295 (DAC) | 8–12 weeks | 6–8 weeks | Long half-life requires longer break | Community convention |
| Ipamorelin + CJC-1295 | 8–12 weeks | 4–8 weeks | Combined stack; same break applies | Community convention |
| GHRP-2 | 8–12 weeks | 4–8 weeks | GHSR desensitization; cortisol elevation noted | Community convention |
| GHRP-6 | 8–12 weeks | 4–8 weeks | GHSR desensitization; strong appetite stimulation | Community convention |
| MK-677 | 12–16 weeks | 4–8 weeks | Not a peptide; oral GH secretagogue; same GHSR mechanism | Community convention |
Tissue Repair and Cognitive Peptide Cycling
| Peptide | On-Cycle | Break | Notes |
|---|---|---|---|
| BPC-157 (injury/repair) | 4–6 weeks | 4–6 weeks | For targeted injury repair; no mechanism-based cycling rationale |
| BPC-157 (preventive) | 4–6 weeks | 4–6 weeks | More cautionary; unknown long-term effects in humans |
| TB-500 (Thymosin β4) | 4–6 weeks | 4–6 weeks | Similar precautionary approach; no desensitization data |
| Semax | 10–14 days | 2–4 weeks | Russian clinical standard; short courses with defined breaks |
| Selank | 10–14 days | 2–4 weeks | Russian clinical standard; mirrors Semax protocol |
| Epitalon | 10–20 days | 4–6 months | Khavinson protocol: 2× per year maximum |
Metabolic Peptide Cycling Table
| Peptide | Cycling Required | Protocol | Evidence |
|---|---|---|---|
| Semaglutide | No | Chronic continuous weekly dosing | Grade A — STEP 1 68-week trial (PMID 33567185) |
| Tirzepatide | No | Chronic continuous weekly dosing | Grade A — SURMOUNT-1 72-week trial (PMID 35658024) |
| Tesamorelin | No (medical) | Continuous daily; HIV lipodystrophy indication | Grade B — FDA approved for chronic use |
| AOD-9604 | Unknown | 12 weeks max (community convention) | Grade D — no human data |
Evidence Grade Callout
Grade A: GLP-1/GIP agonist continuous use (FDA-approved protocol, RCT-backed). Grade C: GH peptide cycling rationale is mechanistically supported (GHSR desensitization is real) but specific cycle durations are community conventions without formal study. Grade D: BPC-157, TB-500, Epitalon cycling durations — no systematic data; precautionary conventions only.
Legal Disclaimer
Cycling protocols for research peptides are community conventions without regulatory approval or clinical validation. FDA-approved peptide pharmaceuticals (semaglutide, tirzepatide) should follow prescribing information only. Research peptides have no approved cycling protocols. This page is for educational reference and does not constitute medical advice.
Related Pages
Sources
- Bowers CY et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID 9849822
- Broglio F et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001;86(10):5083-6. PMID 11600554
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PMID 33567185
Frequently Asked Questions
Why do GH peptides require cycling?
GH secretagogues (ipamorelin, GHRP-2, GHRP-6, CJC-1295) stimulate pituitary somatotroph cells to release GH by binding the growth hormone secretagogue receptor (GHSR). Like most G-protein coupled receptors, GHSR undergoes agonist-induced internalization and desensitization with prolonged continuous stimulation. This reduces GH pulse amplitude over time, diminishing the peptide's effectiveness. Cycling — taking a 4–8 week break after 8–12 weeks of use — allows receptor re-sensitization. This rationale is mechanistically sound but the specific optimal cycle lengths have not been studied in formal human trials.
Does BPC-157 actually need to be cycled?
The cycling rationale for BPC-157 is less mechanistically clear than for GH peptides. BPC-157's primary mechanisms (growth factor upregulation, angiogenesis, anti-inflammatory pathways) do not rely on a single G-protein coupled receptor that would obviously desensitize. The 4–6 on / 4–6 off convention is community-derived and precautionary — acknowledging that long-term effects of continuous BPC-157 use are unknown in humans. For acute tissue repair (post-injury or post-surgery), shorter targeted courses make sense. For continuous use without an injury target, there is no evidence-based protocol.
Why does semaglutide not need cycling?
Semaglutide's GLP-1 receptor engagement, while sustained by the ~7-day half-life, does not produce significant receptor downregulation at therapeutic doses. The FDA-approved chronic administration protocol (ongoing, indefinite weekly dosing) is supported by the STEP trials showing maintained weight loss without tolerance or tachyphylaxis during the 68-week trial period. Weight regain occurs when semaglutide is stopped — which further confirms that receptor sensitivity is maintained during treatment, not lost. Cycling semaglutide would cause weight regain without mechanistic benefit.